10. Non-Hodgkin lymphoma

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Ross Pinkerton

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch10

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Pinkerton, R. (2013) Non-Hodgkin lymphoma, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch10

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. Royal Children's Hospital, Brisbane, QLD, Australia

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309



  • anaplastic large cell lymphoma (ALCL);
  • Burkitt lymphoma (BL);
  • cancer;
  • chemotherapy;
  • children;
  • non-Hodgkin lymphoma (NHL)


The evolution of curative strategies for the more common childhood non-Hodgkin lymphomas (NHL) has been influenced by advances in adult cancer, children's cancer and, more recently, international initiatives. A recent Cochrane review attempted to assess the evidence regarding chemotherapy, surgery, radiotherapy, and immunotherapy in Burkitt lymphoma (BL). This included 13 randomized trials from as far back as 1971. With contemporary immunohistochemistry and molecular genetics, anaplastic large cell lymphoma (ALCL) contributes 10% of NHL in children. Little has been learned in the past from studies when the tumor was included in an assortment of other tumor types. It is likely that over the next few years, trials in children will focus on the role of monoclonal antibodies and it is becoming increasingly difficult for practitioners to resist simply following the adult practice in high-grade NHL.